FDA has approved KORSUVA for the treatment of moderate to severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Cara Therapeutics has agreed with Vifor Pharma for an exclusive license to commercialize KORSUVA in the United States. The agreement provides for profit sharing in the proportion of Cara 50% and Vifor 50% in clinics affiliated with Fresenius Medical Care. At the other clinics - in the proportion of Cara 60% and Vifor 40%.
FDA has approved KORSUVA for the treatment of moderate to severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Cara Therapeutics has agreed with Vifor Pharma for an exclusive license to commercialize KORSUVA in the United States. The agreement provides for profit sharing in the proportion of Cara 50% and Vifor 50% in clinics affiliated with Fresenius Medical Care. At the other clinics - in the proportion of Cara 60% and Vifor 40%. 
ir.caratherapeutics.com
English (US) 